Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launchPotassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials".

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹2172.00

prior close

₹2172.50

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.6+0.8+1.0+1.4-1.3+0.5-3.1+0.4-4.2-0.3-0.6+3.6+8.3-0.6

Up moveDown movePending

AI summary

Glenmark Pharmaceuticals Inc., USA is set to launch Potassium Phosphates Injection USP in three formats — single-dose vials (5 mL and 15 mL) and pharmacy bulk package vials (50 mL) — with distribution beginning in March 2026. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi's reference listed drug (NDA 212832). According to IQVIA data for the 12 months ending January 2026, the U.S. market for this product is approximately $50.7 million annually. The launch strengthens Glenmark's injectable portfolio in the U.S. institutional channel, with the company's North America head Marc Kikuchi highlighting the focus on affordable alternatives for patients.

Likely market impact

Positive for shareholders — adds a new revenue stream in a ~$50.7 million U.S. market and expands Glenmark's injectable generics portfolio, though pricing pressure from competition with Fresenius Kabi may limit margin gains.